AustralieFrV1, Main, Exploration, bibRecord, 004A38

Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure

Identifieur interne : 004A38 ( Main/Exploration ); précédent : 004A37; suivant : 004A39

Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure

Auteurs : Michel Komajda [France] ; Michael Böhm [Allemagne] ; Jeffrey Borer [États-Unis] ; Ian Ford [Royaume-Uni] ; Henry Krum [Australie] ; Adrian Tase [Roumanie] ; Luigi Tavazzi [Italie] ; Karl Swedberg [Suède]

Source :

European Journal of Heart Failure [ 1388-9842 ] ; 2013-01.

RBID : ISTEX:CFB054595A9FAC926E7901E172BB0491156053A6

English descriptors

Abstract

A post‐hoc analysis of the SHIFT trial was performed to explore whether ivabradine is beneficial in patients with systolic heart failure, in sinus rhythm, with resting heart rate ≥70 b.p.m., and whose guideline‐recommended background therapy includes a mineralocorticoid receptor antagonist (MRA).

Url:

https://api.istex.fr/document/CFB054595A9FAC926E7901E172BB0491156053A6/fulltext/pdf

DOI: 10.1093/eurjhf/hfs127

Affiliations:

Allemagne, Australie, France, Italie, Roumanie, Royaume-Uni, Suède, États-Unis
Victoria (État), Écosse, Île-de-France
Glasgow, Melbourne, Paris
Université de Glasgow

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 002677
to stream Istex, to step Curation: 002677
to stream Istex, to step Checkpoint: 000348
to stream Main, to step Merge: 004B62
to stream Main, to step Curation: 004A38

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure</title>
<author><name sortKey="Komajda, Michel" sort="Komajda, Michel" uniqKey="Komajda M" first="Michel" last="Komajda">Michel Komajda</name>
</author>
<author><name sortKey="Bohm, Michael" sort="Bohm, Michael" uniqKey="Bohm M" first="Michael" last="Böhm">Michael Böhm</name>
</author>
<author><name sortKey="Borer, Jeffrey" sort="Borer, Jeffrey" uniqKey="Borer J" first="Jeffrey" last="Borer">Jeffrey Borer</name>
</author>
<author><name sortKey="Ford, Ian" sort="Ford, Ian" uniqKey="Ford I" first="Ian" last="Ford">Ian Ford</name>
</author>
<author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name>
</author>
<author><name sortKey="Tase, Adrian" sort="Tase, Adrian" uniqKey="Tase A" first="Adrian" last="Tase">Adrian Tase</name>
</author>
<author><name sortKey="Tavazzi, Luigi" sort="Tavazzi, Luigi" uniqKey="Tavazzi L" first="Luigi" last="Tavazzi">Luigi Tavazzi</name>
</author>
<author><name sortKey="Swedberg, Karl" sort="Swedberg, Karl" uniqKey="Swedberg K" first="Karl" last="Swedberg">Karl Swedberg</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:CFB054595A9FAC926E7901E172BB0491156053A6</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1093/eurjhf/hfs127</idno>
<idno type="url">https://api.istex.fr/document/CFB054595A9FAC926E7901E172BB0491156053A6/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002677</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002677</idno>
<idno type="wicri:Area/Istex/Curation">002677</idno>
<idno type="wicri:Area/Istex/Checkpoint">000348</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000348</idno>
<idno type="wicri:doubleKey">1388-9842:2013:Komajda M:influence:of:background</idno>
<idno type="wicri:Area/Main/Merge">004B62</idno>
<idno type="wicri:Area/Main/Curation">004A38</idno>
<idno type="wicri:Area/Main/Exploration">004A38</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure</title>
<author><name sortKey="Komajda, Michel" sort="Komajda, Michel" uniqKey="Komajda M" first="Michel" last="Komajda">Michel Komajda</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Cardiology, Université Pierre et Marie Curie Paris VI, La Pitié‐Salpétrière Hospital, 75013, Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">France</country>
</affiliation>
</author>
<author><name sortKey="Bohm, Michael" sort="Bohm, Michael" uniqKey="Bohm M" first="Michael" last="Böhm">Michael Böhm</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Universitätskliniken des Saarlandes, Klinik für Innere Medizin III, Homburg/Saar</wicri:regionArea>
<wicri:noRegion>Homburg/Saar</wicri:noRegion>
<wicri:noRegion>Homburg/Saar</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Borer, Jeffrey" sort="Borer, Jeffrey" uniqKey="Borer J" first="Jeffrey" last="Borer">Jeffrey Borer</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, Division of Cardiovascular Medicine and the Howard Gilman Institute for Heart Valve Disease, State University of New York Downstate Medical Center, NY, Brooklyn and New York</wicri:regionArea>
<wicri:noRegion>Brooklyn and New York</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ford, Ian" sort="Ford, Ian" uniqKey="Ford I" first="Ian" last="Ford">Ian Ford</name>
<affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Robertson Centre for Biostatistics, University of Glasgow</wicri:regionArea>
<placeName><settlement type="city">Glasgow</settlement>
<region type="country">Écosse</region>
</placeName>
<orgName type="university">Université de Glasgow</orgName>
</affiliation>
</author>
<author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name>
<affiliation wicri:level="3"><country xml:lang="fr">Australie</country>
<wicri:regionArea>Centre of Clinical Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University, Victoria, Melbourne</wicri:regionArea>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tase, Adrian" sort="Tase, Adrian" uniqKey="Tase A" first="Adrian" last="Tase">Adrian Tase</name>
<affiliation wicri:level="1"><country xml:lang="fr">Roumanie</country>
<wicri:regionArea>Department of Cardiology, University of Pitesti, Emergency Hospital Arges, Pitesti</wicri:regionArea>
<wicri:noRegion>Pitesti</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tavazzi, Luigi" sort="Tavazzi, Luigi" uniqKey="Tavazzi L" first="Luigi" last="Tavazzi">Luigi Tavazzi</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Maria Cecilia Hospital–GVM Care and Research, Ettore Sansavini Health Science Foundation, Cotignola</wicri:regionArea>
<wicri:noRegion>Cotignola</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Swedberg, Karl" sort="Swedberg, Karl" uniqKey="Swedberg K" first="Karl" last="Swedberg">Karl Swedberg</name>
<affiliation wicri:level="1"><country xml:lang="fr">Suède</country>
<wicri:regionArea>Section of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg</wicri:regionArea>
<wicri:noRegion>Göteborg</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">European Journal of Heart Failure</title>
<title level="j" type="alt">EUROPEAN JOURNAL OF HEART FAILURE</title>
<idno type="ISSN">1388-9842</idno>
<idno type="eISSN">1879-0844</idno>
<imprint><biblScope unit="vol">15</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="79">79</biblScope>
<biblScope unit="page" to="84">84</biblScope>
<biblScope unit="page-count">6</biblScope>
<date type="published" when="2013-01">2013-01</date>
</imprint>
<idno type="ISSN">1388-9842</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1388-9842</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adverse events</term>
<term>Angiotensin receptor blocker</term>
<term>Baseline</term>
<term>Baseline characteristics</term>
<term>Blocker</term>
<term>Cardiovascular</term>
<term>Cardiovascular death</term>
<term>Categorical variables</term>
<term>Chronic heart failure</term>
<term>Dysfunction</term>
<term>Endpoint</term>
<term>Eplerenone</term>
<term>European society</term>
<term>Heart failure</term>
<term>Heart failure hospitalization</term>
<term>Heart failure patients</term>
<term>Heart rate</term>
<term>Hospitalization</term>
<term>Infarction</term>
<term>Ivabradine</term>
<term>Komajda</term>
<term>Ltration rate</term>
<term>Mineralocorticoid</term>
<term>Mineralocorticoid receptor antagonist</term>
<term>Mineralocorticoid receptor antagonists</term>
<term>Mras</term>
<term>Nyha</term>
<term>Nyha class</term>
<term>Placebo</term>
<term>Placebo group</term>
<term>Prognostic factors</term>
<term>Proportional hazards model</term>
<term>Receptor</term>
<term>Severe heart failure</term>
<term>Shift trial</term>
<term>Sinus rhythm</term>
<term>Subpopulation</term>
<term>Systolic</term>
<term>Systolic dysfunction</term>
<term>Zannad</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Adverse events</term>
<term>Angiotensin receptor blocker</term>
<term>Baseline</term>
<term>Baseline characteristics</term>
<term>Blocker</term>
<term>Cardiovascular</term>
<term>Cardiovascular death</term>
<term>Categorical variables</term>
<term>Chronic heart failure</term>
<term>Dysfunction</term>
<term>Endpoint</term>
<term>Eplerenone</term>
<term>European society</term>
<term>Heart failure</term>
<term>Heart failure hospitalization</term>
<term>Heart failure patients</term>
<term>Heart rate</term>
<term>Hospitalization</term>
<term>Infarction</term>
<term>Ivabradine</term>
<term>Komajda</term>
<term>Ltration rate</term>
<term>Mineralocorticoid</term>
<term>Mineralocorticoid receptor antagonist</term>
<term>Mineralocorticoid receptor antagonists</term>
<term>Mras</term>
<term>Nyha</term>
<term>Nyha class</term>
<term>Placebo</term>
<term>Placebo group</term>
<term>Prognostic factors</term>
<term>Proportional hazards model</term>
<term>Receptor</term>
<term>Severe heart failure</term>
<term>Shift trial</term>
<term>Sinus rhythm</term>
<term>Subpopulation</term>
<term>Systolic</term>
<term>Systolic dysfunction</term>
<term>Zannad</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">A post‐hoc analysis of the SHIFT trial was performed to explore whether ivabradine is beneficial in patients with systolic heart failure, in sinus rhythm, with resting heart rate ≥70 b.p.m., and whose guideline‐recommended background therapy includes a mineralocorticoid receptor antagonist (MRA).</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>France</li>
<li>Italie</li>
<li>Roumanie</li>
<li>Royaume-Uni</li>
<li>Suède</li>
<li>États-Unis</li>
</country>
<region><li>Victoria (État)</li>
<li>Écosse</li>
<li>Île-de-France</li>
</region>
<settlement><li>Glasgow</li>
<li>Melbourne</li>
<li>Paris</li>
</settlement>
<orgName><li>Université de Glasgow</li>
</orgName>
</list>
<tree><country name="France"><region name="Île-de-France"><name sortKey="Komajda, Michel" sort="Komajda, Michel" uniqKey="Komajda M" first="Michel" last="Komajda">Michel Komajda</name>
</region>
<name sortKey="Komajda, Michel" sort="Komajda, Michel" uniqKey="Komajda M" first="Michel" last="Komajda">Michel Komajda</name>
</country>
<country name="Allemagne"><noRegion><name sortKey="Bohm, Michael" sort="Bohm, Michael" uniqKey="Bohm M" first="Michael" last="Böhm">Michael Böhm</name>
</noRegion>
</country>
<country name="États-Unis"><noRegion><name sortKey="Borer, Jeffrey" sort="Borer, Jeffrey" uniqKey="Borer J" first="Jeffrey" last="Borer">Jeffrey Borer</name>
</noRegion>
</country>
<country name="Royaume-Uni"><region name="Écosse"><name sortKey="Ford, Ian" sort="Ford, Ian" uniqKey="Ford I" first="Ian" last="Ford">Ian Ford</name>
</region>
</country>
<country name="Australie"><region name="Victoria (État)"><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name>
</region>
</country>
<country name="Roumanie"><noRegion><name sortKey="Tase, Adrian" sort="Tase, Adrian" uniqKey="Tase A" first="Adrian" last="Tase">Adrian Tase</name>
</noRegion>
</country>
<country name="Italie"><noRegion><name sortKey="Tavazzi, Luigi" sort="Tavazzi, Luigi" uniqKey="Tavazzi L" first="Luigi" last="Tavazzi">Luigi Tavazzi</name>
</noRegion>
</country>
<country name="Suède"><noRegion><name sortKey="Swedberg, Karl" sort="Swedberg, Karl" uniqKey="Swedberg K" first="Karl" last="Swedberg">Karl Swedberg</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004A38 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004A38 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:CFB054595A9FAC926E7901E172BB0491156053A6
   |texte=   Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure

Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri